BriaCell Therapeutics Announces $8.5M Best-Efforts Offering Of 12.325M Common Shares At A Price Of $0.69/Share
Portfolio Pulse from Benzinga Newsdesk
BriaCell Therapeutics announced an $8.5 million best-efforts offering of 12.325 million common shares at $0.69 per share. The proceeds will be used for working capital, corporate purposes, and business advancement. The offering is expected to close on September 12, 2024.
September 11, 2024 | 4:14 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
BriaCell Therapeutics is conducting an $8.5 million offering of 12.325 million shares at $0.69 each. The funds will support working capital and business objectives. The offering may dilute existing shares, potentially impacting stock price.
The offering of new shares at $0.69 each could lead to dilution of existing shares, which may negatively impact the stock price in the short term. The funds raised are intended for working capital and business advancement, which is positive for long-term growth.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100